Treatment of mst1r related diseases and disorders
AssigneeEmpirico Inc.
InventorsOmri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions comprising an oligonucleotide that targets MST1R. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1R mutations that include providing an oligonucleotide that targets MST1R to a subject.
Claims28
A composition comprising an oligonucleotide that targets MST1R and when administered to a subject in an effective amount improves:
- (a) a lung function measurement;
- (b) a leukocyte measurement;
- (c) a chronic obstructive pulomonary disease (COPD) symptom or exacerbation measurement;
- or
- (d) an asthma symptom or exacerbation measurement.
3-10. (canceled)
(canceled)
17-21. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A composition comprising an oligonucleotide that inhibits the expression of MST1R, wherein the oligonucleotide comprises
- (a) an siRNA comprising a sense strand and an antisense strand, each strand is independently 12-30 nucleosides in length, and at least one of the sense strand and the antisense strand comprises a nucleoside sequence comprising 12-30 contiguous nucleosides of SEQ ID NO:
- 9818;
- or
- (b) antisense oligonucleotide (ASO) comprising 12-30 nucleosides in length and a nucleoside sequence complementary to about 12-30 contiguous nucleosides of SEQ ID NO:
- 9818.
34-36. (canceled)
A method of treating a subject having a lung disorder, comprising administering an effective amount of a composition comprising an oligonucleotide that modulates the expression of MST1R, wherein the oligonucleotide comprises
- (a) an siRNA comprising a sense strand and an antisense strand, each strand is independently about 12-30 nucleosides in length, and at least one of the sense strand and the antisense strand comprises a nucleoside sequence comprising about 12-30 contiguous nucleosides of SEQ ID NO:
- 9818;
- or
- (b) antisense oligonucleotide (ASO) comprising 12-30 nucleosides in length and a nucleoside sequence complementary to about 12-30 contiguous nucleosides of SEQ ID NO:
- 9818 to the subject.
Dependencies are inferred from the claim text.